1
|
Li J, Lv Y, Chen Z, Zhao J, Wang S. Citric Acid Loaded Hydrogel-Coated Stent for Dissolving Pancreatic Duct Calculi. Gels 2024; 10:125. [PMID: 38391455 PMCID: PMC10888429 DOI: 10.3390/gels10020125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2023] [Revised: 01/26/2024] [Accepted: 01/29/2024] [Indexed: 02/24/2024] Open
Abstract
In recent years, the incidence of chronic pancreatitis has increased significantly. Pancreatic calculi obstruct the pancreatic duct and induce abdominal pain in the patients. Pancreatic duct stenting is the major treatment option for chronic pancreatitis with calculi. In this study, a new kind of drug-eluting stent, a pancreatic stent coated by methacrylated gelatin (GelMA) hydrogel loaded with citric acid (CA), was designed for the interventional treatment of pancreatic duct calculi. The CA loading capacity reached up to 0.7 g CA/g hydrogel-coated stent. The GelMA hydrogel coating has higher mechanical strength and lower swelling performance after loading with CA. The in vitro experiments of stents exhibited good performance in CA sustained release and the calculi can be dissolved in almost 3 days. The stents also showed good blood compatibility and cell compatibility. This research has important clinical value in the treatment of chronic pancreatitis with pancreatic calculi.
Collapse
Affiliation(s)
- Jing Li
- School of Materials and Chemistry, University of Shanghai for Science and Technology, No. 334 Jungong Road, Shanghai 200093, China
- Public Experiment Center, University of Shanghai for Science and Technology, No. 334 Jungong Road, Shanghai 200093, China
| | - Yanwei Lv
- Department of Gastroenterology, Changhai Hospital, Naval Medical University, No. 168 Changhai Road, Shanghai 200433, China
| | - Zheng Chen
- School of Materials and Chemistry, University of Shanghai for Science and Technology, No. 334 Jungong Road, Shanghai 200093, China
| | - Jiulong Zhao
- Department of Gastroenterology, Changhai Hospital, Naval Medical University, No. 168 Changhai Road, Shanghai 200433, China
| | - Shige Wang
- School of Materials and Chemistry, University of Shanghai for Science and Technology, No. 334 Jungong Road, Shanghai 200093, China
| |
Collapse
|
2
|
Zhou Z, Li K, Guo Y, Liu P, Chen Q, Fan H, Sun T, Jiang C. ROS/Electro Dual-Reactive Nanogel for Targeting Epileptic Foci to Remodel Aberrant Circuits and Inflammatory Microenvironment. ACS NANO 2023; 17:7847-7864. [PMID: 37039779 DOI: 10.1021/acsnano.3c01140] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/09/2023]
Abstract
Medicinal treatment against epilepsy is faced with intractable problems, especially epileptogenesis that cannot be blocked by clinical antiepileptic drugs (AEDs) during the latency of epilepsy. Abnormal circuits of neurons interact with the inflammatory microenvironment of glial cells in epileptic foci, resulting in recurrent seizures and refractory epilepsy. Herein, we have selected phenytoin (PHT) as a model drug to derive a ROS-responsive and consuming prodrug, which is combined with an electro-responsive group (sulfonate sodium, SS) and an epileptic focus-recognizing group (α-methyl-l-tryptophan, AMT) to form hydrogel nanoparticles (i.e., a nanogel). The nanogel will target epileptic foci, release PHT in response to a high concentration of reactive oxygen species (ROS) in the microenvironment, and inhibit overexcited circuits. Meanwhile, with the clearance of ROS, the nanogel can also reduce oxidative stress and alleviate microenvironment inflammation. Thus, a synergistic regulation of epileptic lesions will be achieved. Our nanogel is expected to provide a more comprehensive strategy for antiepileptic treatment.
Collapse
Affiliation(s)
- Zheng Zhou
- Department of Pharmaceutics, School of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery, Ministry of Education, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai 201203, People's Republic of China
| | - Keying Li
- Department of Pharmaceutics, School of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery, Ministry of Education, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai 201203, People's Republic of China
| | - Yun Guo
- Department of Pharmaceutics, School of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery, Ministry of Education, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai 201203, People's Republic of China
| | - Peixin Liu
- Department of Pharmaceutics, School of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery, Ministry of Education, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai 201203, People's Republic of China
| | - Qinjun Chen
- Department of Pharmaceutics, School of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery, Ministry of Education, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai 201203, People's Republic of China
| | - Hongrui Fan
- Department of Pharmaceutics, School of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery, Ministry of Education, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai 201203, People's Republic of China
| | - Tao Sun
- Department of Pharmaceutics, School of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery, Ministry of Education, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai 201203, People's Republic of China
| | - Chen Jiang
- Department of Pharmaceutics, School of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery, Ministry of Education, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai 201203, People's Republic of China
| |
Collapse
|
3
|
Zhou Z, Li K, Chu Y, Li C, Zhang T, Liu P, Sun T, Jiang C. ROS-removing nano-medicine for navigating inflammatory microenvironment to enhance anti-epileptic therapy. Acta Pharm Sin B 2022; 13:1246-1261. [PMID: 36970212 PMCID: PMC10031259 DOI: 10.1016/j.apsb.2022.09.019] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2022] [Revised: 08/29/2022] [Accepted: 09/15/2022] [Indexed: 11/01/2022] Open
Abstract
As a neurological disorder in the brain, epilepsy is not only associated with abnormal synchronized discharging of neurons, but also inseparable from non-neuronal elements in the altered microenvironment. Anti-epileptic drugs (AEDs) merely focusing on neuronal circuits frequently turn out deficient, which is necessitating comprehensive strategies of medications to cover over-exciting neurons, activated glial cells, oxidative stress and chronic inflammation synchronously. Therefore, we would report the design of a polymeric micelle drug delivery system that was functioned with brain targeting and cerebral microenvironment modulation. In brief, reactive oxygen species (ROS)-sensitive phenylboronic ester was conjugated with poly-ethylene glycol (PEG) to form amphiphilic copolymers. Additionally, dehydroascorbic acid (DHAA), an analogue of glucose, was applied to target glucose transporter 1 (GLUT1) and facilitate micelle penetration across the blood‒brain barrier (BBB). A classic hydrophobic AED, lamotrigine (LTG), was encapsulated in the micelles via self-assembly. When administrated and transferred across the BBB, ROS-scavenging polymers were expected to integrate anti-oxidation, anti-inflammation and neuro-electric modulation into one strategy. Moreover, micelles would alter LTG distribution in vivo with improved efficacy. Overall, the combined anti-epileptic therapy might provide effective opinions on how to maximize neuroprotection during early epileptogenesis.
Collapse
|
4
|
Kim YH, Dawson JI, Oreffo ROC, Tabata Y, Kumar D, Aparicio C, Mutreja I. Gelatin Methacryloyl Hydrogels for Musculoskeletal Tissue Regeneration. BIOENGINEERING (BASEL, SWITZERLAND) 2022; 9:bioengineering9070332. [PMID: 35877383 PMCID: PMC9311920 DOI: 10.3390/bioengineering9070332] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/18/2022] [Revised: 07/11/2022] [Accepted: 07/14/2022] [Indexed: 12/30/2022]
Abstract
Musculoskeletal disorders are a significant burden on the global economy and public health. Hydrogels have significant potential for enhancing the repair of damaged and injured musculoskeletal tissues as cell or drug delivery systems. Hydrogels have unique physicochemical properties which make them promising platforms for controlling cell functions. Gelatin methacryloyl (GelMA) hydrogel in particular has been extensively investigated as a promising biomaterial due to its tuneable and beneficial properties and has been widely used in different biomedical applications. In this review, a detailed overview of GelMA synthesis, hydrogel design and applications in regenerative medicine is provided. After summarising recent progress in hydrogels more broadly, we highlight recent advances of GelMA hydrogels in the emerging fields of musculoskeletal drug delivery, involving therapeutic drugs (e.g., growth factors, antimicrobial molecules, immunomodulatory drugs and cells), delivery approaches (e.g., single-, dual-release system), and material design (e.g., addition of organic or inorganic materials, 3D printing). The review concludes with future perspectives and associated challenges for developing local drug delivery for musculoskeletal applications.
Collapse
Affiliation(s)
- Yang-Hee Kim
- Bone and Joint Research Group, Centre for Human Development, Stem Cells & Regeneration, Institute of Developmental Sciences, University of Southampton, Southampton SO16 6YD, UK; (J.I.D.); (R.O.C.O.)
- Correspondence: (Y.-H.K.); (I.M.); Tel.: +44-2381-203293 (Y.-H.K.); +1-(612)7605790 (I.M.)
| | - Jonathan I. Dawson
- Bone and Joint Research Group, Centre for Human Development, Stem Cells & Regeneration, Institute of Developmental Sciences, University of Southampton, Southampton SO16 6YD, UK; (J.I.D.); (R.O.C.O.)
| | - Richard O. C. Oreffo
- Bone and Joint Research Group, Centre for Human Development, Stem Cells & Regeneration, Institute of Developmental Sciences, University of Southampton, Southampton SO16 6YD, UK; (J.I.D.); (R.O.C.O.)
| | - Yasuhiko Tabata
- Department of Biomaterials, Field of Tissue Engineering, Institute for Frontier Medical Sciences, Kyoto University, Kyoto 606-8501, Japan;
| | - Dhiraj Kumar
- Division of Pediatric Dentistry, School of Dentistry, University of Minnesota, Minneapolis, MN 55812, USA;
| | - Conrado Aparicio
- Minnesota Dental Research Center for Biomaterials and Biomechanics, Department of Restorative Science, University of Minnesota, Minneapolis, MN 55455, USA;
- Division of Basic Research, Faculty of Odontology UIC Barcelona—Universitat Internacional de Catalunya, 08017 Barcelona, Spain
- BIST—Barcelona Institute for Science and Technology, 08195 Barcelona, Spain
| | - Isha Mutreja
- Minnesota Dental Research Center for Biomaterials and Biomechanics, Department of Restorative Science, University of Minnesota, Minneapolis, MN 55455, USA;
- Correspondence: (Y.-H.K.); (I.M.); Tel.: +44-2381-203293 (Y.-H.K.); +1-(612)7605790 (I.M.)
| |
Collapse
|
5
|
Chen Y, Chen J, Chen Y, Li Y. miR-146a/KLF4 axis in epileptic mice: a novel regulator of synaptic plasticity involving STAT3 signaling. Brain Res 2022; 1790:147988. [PMID: 35728661 DOI: 10.1016/j.brainres.2022.147988] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2021] [Revised: 06/05/2022] [Accepted: 06/15/2022] [Indexed: 11/02/2022]
Abstract
OBJECTIVE This study is aimed to investigate the mechanism of miR-146a/KLF4 axis regarding epilepsy seizure and synaptic plasticity. METHODS Pentylenetetrazol (PTZ)-kindling mouse model of epilepsy was established and evaluated by Racine's scale. PTZ-treated mice were subjected to stereotactic injection of miR-146a antagomir and pre-KLF4 to verify the role of miR-146a and KLF4 in mice. Primary hippocampal neurons from fetal mouse were isolated and identified through immunofluorescence for microtubule-associated protein (MAP)-2. Cellular models of epilepsy were prepared using magnesium-free extracellular fluid and then the neurons were transfected with miR-146a antagomir, miR-146a agomir, miR-146a agomir + pre-KLF4, AG490 (an inhibitor of STAT3 signal pathway) or miR-146a agomir + AG490. The binding site between miR-146a and KLF4 was predicted and identified. The expression levels of miR-146a, KLF4, CREB, Synaptotagmin-11 (SYT11), and STAT3-related proteins were measured in addition to the morphology of neurons and length of neurite. The severity of synaptic plasticity was assessed according to the levels of CREB and SYT11. RESULTS The expression of miR-146a was elevated and KLF4 expression was decreased in epileptic mice. Stereotactic injection of miR-146a antagomir and pre-KLF4 reduced the seizure scores of epileptic mice. Transfection of miR-146a antagomir or pre-KLF4 could attenuate synaptic plasticity in epileptic mice and epileptic cellular models. miR-146a can negatively regulate KLF4 in epileptic cellular models to mediate synaptic plasticity. Epilepsy was attenuated in AG490 and miR-146a agomir + AG490 groups compared with that in Model group. CONCLUSION miR-146a inhibits KLF4 to activate STAT3, thus promoting synaptic plasticity in epileptic mice.
Collapse
Affiliation(s)
- Ying Chen
- Department of Neurology, the First Hospital of Changsha, Changsha, Hunan 410005, PR China.
| | - Juan Chen
- Department of Neurology, the First Hospital of Changsha, Changsha, Hunan 410005, PR China
| | - Yu Chen
- Department of Neurology, the First Hospital of Changsha, Changsha, Hunan 410005, PR China
| | - Yuan Li
- Department of Neurology, the First Hospital of Changsha, Changsha, Hunan 410005, PR China
| |
Collapse
|
6
|
Abstract
AbstractThe multidisciplinary research field of bioprinting combines additive manufacturing, biology and material sciences to create bioconstructs with three-dimensional architectures mimicking natural living tissues. The high interest in the possibility of reproducing biological tissues and organs is further boosted by the ever-increasing need for personalized medicine, thus allowing bioprinting to establish itself in the field of biomedical research, and attracting extensive research efforts from companies, universities, and research institutes alike. In this context, this paper proposes a scientometric analysis and critical review of the current literature and the industrial landscape of bioprinting to provide a clear overview of its fast-changing and complex position. The scientific literature and patenting results for 2000–2020 are reviewed and critically analyzed by retrieving 9314 scientific papers and 309 international patents in order to draw a picture of the scientific and industrial landscape in terms of top research countries, institutions, journals, authors and topics, and identifying the technology hubs worldwide. This review paper thus offers a guide to researchers interested in this field or to those who simply want to understand the emerging trends in additive manufacturing and 3D bioprinting.
Graphic abstract
Collapse
|
7
|
Remy MT, Akkouch A, He L, Eliason S, Sweat ME, Krongbaramee T, Fei F, Qian F, Amendt BA, Song X, Hong L. Rat Calvarial Bone Regeneration by 3D-Printed β-Tricalcium Phosphate Incorporating MicroRNA-200c. ACS Biomater Sci Eng 2021; 7:4521-4534. [PMID: 34437807 PMCID: PMC8441974 DOI: 10.1021/acsbiomaterials.0c01756] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
![]()
Advanced fabrication
methods for bone grafts designed to match
defect sites that combine biodegradable, osteoconductive materials
with potent, osteoinductive biologics would significantly impact the
clinical treatment of large bone defects. In this study, we engineered
synthetic bone grafts using a hybrid approach that combined three-dimensional
(3D-)printed biodegradable, osteoconductive β-tricalcium phosphate
(β-TCP) with osteoinductive microRNA(miR)-200c. 3D-printed β-TCP
scaffolds were fabricated utilizing a suspension-enclosing projection-stereolithography
(SEPS) process to produce constructs with reproducible microarchitectures
that enhanced the osteoconductive properties of β-TCP. Collagen
coating on 3D-printed β-TCP scaffolds slowed the release of
plasmid DNA encoding miR-200c compared to noncoated
constructs. 3D-printed β-TCP scaffolds coated with miR-200c-incorporated collagen increased the transfection efficiency of miR-200c of both rat and human BMSCs and additionally increased
osteogenic differentiation of hBMSCs in vitro. Furthermore, miR-200c-incorporated scaffolds significantly enhanced bone
regeneration in critical-sized rat calvarial defects. These results
strongly indicate that bone grafts combining SEPS 3D-printed osteoconductive
biomaterial-based scaffolds with osteoinductive miR-200c can be used
as superior bone substitutes for the clinical treatment of large bone
defects.
Collapse
Affiliation(s)
- Matthew T Remy
- Iowa Institute for Oral Health Research, College of Dentistry, The University of Iowa, Iowa City, Iowa 52242, United States
| | - Adil Akkouch
- Iowa Institute for Oral Health Research, College of Dentistry, The University of Iowa, Iowa City, Iowa 52242, United States
| | - Li He
- Department of Industrial and Systems Engineering, College of Engineering, The University of Iowa, Iowa City, Iowa 52242, United States
| | - Steven Eliason
- Department of Anatomy and Cell Biology, Carver College of Medicine, The University of Iowa, Iowa City, Iowa 52242, United States
| | - Mason E Sweat
- Department of Industrial and Systems Engineering, College of Engineering, The University of Iowa, Iowa City, Iowa 52242, United States
| | - Tadkamol Krongbaramee
- Iowa Institute for Oral Health Research, College of Dentistry, The University of Iowa, Iowa City, Iowa 52242, United States
| | - Fan Fei
- Department of Industrial and Systems Engineering, College of Engineering, The University of Iowa, Iowa City, Iowa 52242, United States
| | - Fang Qian
- Iowa Institute for Oral Health Research, College of Dentistry, The University of Iowa, Iowa City, Iowa 52242, United States
| | - Brad A Amendt
- Iowa Institute for Oral Health Research, College of Dentistry, The University of Iowa, Iowa City, Iowa 52242, United States.,Department of Anatomy and Cell Biology, Carver College of Medicine, The University of Iowa, Iowa City, Iowa 52242, United States.,Center for Craniofacial Anomalies Research, Carver College of Medicine, The University of Iowa, Iowa City, Iowa 52242, United States
| | - Xuan Song
- Department of Industrial and Systems Engineering, College of Engineering, The University of Iowa, Iowa City, Iowa 52242, United States
| | - Liu Hong
- Iowa Institute for Oral Health Research, College of Dentistry, The University of Iowa, Iowa City, Iowa 52242, United States.,Center for Craniofacial Anomalies Research, Carver College of Medicine, The University of Iowa, Iowa City, Iowa 52242, United States
| |
Collapse
|
8
|
Zhou Z, Sun T, Jiang C. Recent advances on drug delivery nanocarriers for cerebral disorders. Biomed Mater 2021; 16:024104. [PMID: 33455956 DOI: 10.1088/1748-605x/abdc97] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Pharmacotherapies for brain disorders are generally faced with obstacles from the blood-brain barrier (BBB). There are a variety of drug delivery systems that have been put forward to cross or bypass the BBB with the access to the central nervous system. Brain drug delivery systems have benefited greatly from the development of nanocarriers, including lipids, polymers and inorganic materials. Consequently, various kinds of brain drug delivery nano-systems have been established, such as liposomes, polymeric nanoparticles (PNPs), nanomicelles, nanohydrogels, dendrimers, mesoporous silica nanoparticles and magnetic iron oxide nanoparticles. The characteristics of their carriers and preparations usually differ from each other, as well as their transportation mechanisms into intracerebral lesions. In this review, different types of brain drug delivery nanocarriers are classified and summarized, especially their significant achievements, to present several recommendations and directions for future strategies of cerebral delivery.
Collapse
Affiliation(s)
- Zheng Zhou
- Key Laboratory of Smart Drug Delivery (Ministry of Education), State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Department of Pharmaceutics, School of Pharmacy, Fudan University, Shanghai 201203, People's Republic of China
| | | | | |
Collapse
|
9
|
Gernert M, Feja M. Bypassing the Blood-Brain Barrier: Direct Intracranial Drug Delivery in Epilepsies. Pharmaceutics 2020; 12:pharmaceutics12121134. [PMID: 33255396 PMCID: PMC7760299 DOI: 10.3390/pharmaceutics12121134] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2020] [Revised: 11/18/2020] [Accepted: 11/21/2020] [Indexed: 02/06/2023] Open
Abstract
Epilepsies are common chronic neurological diseases characterized by recurrent unprovoked seizures of central origin. The mainstay of treatment involves symptomatic suppression of seizures with systemically applied antiseizure drugs (ASDs). Systemic pharmacotherapies for epilepsies are facing two main challenges. First, adverse effects from (often life-long) systemic drug treatment are common, and second, about one-third of patients with epilepsy have seizures refractory to systemic pharmacotherapy. Especially the drug resistance in epilepsies remains an unmet clinical need despite the recent introduction of new ASDs. Apart from other hypotheses, epilepsy-induced alterations of the blood-brain barrier (BBB) are thought to prevent ASDs from entering the brain parenchyma in necessary amounts, thereby being involved in causing drug-resistant epilepsy. Although an invasive procedure, bypassing the BBB by targeted intracranial drug delivery is an attractive approach to circumvent BBB-associated drug resistance mechanisms and to lower the risk of systemic and neurologic adverse effects. Additionally, it offers the possibility of reaching higher local drug concentrations in appropriate target regions while minimizing them in other brain or peripheral areas, as well as using otherwise toxic drugs not suitable for systemic administration. In our review, we give an overview of experimental and clinical studies conducted on direct intracranial drug delivery in epilepsies. We also discuss challenges associated with intracranial pharmacotherapy for epilepsies.
Collapse
Affiliation(s)
- Manuela Gernert
- Department of Pharmacology, Toxicology, and Pharmacy, University of Veterinary Medicine Hannover, Bünteweg 17, D-30559 Hannover, Germany;
- Center for Systems Neuroscience, D-30559 Hannover, Germany
- Correspondence: ; Tel.: +49-(0)511-953-8527
| | - Malte Feja
- Department of Pharmacology, Toxicology, and Pharmacy, University of Veterinary Medicine Hannover, Bünteweg 17, D-30559 Hannover, Germany;
- Center for Systems Neuroscience, D-30559 Hannover, Germany
| |
Collapse
|
10
|
Löscher W, Friedman A. Structural, Molecular, and Functional Alterations of the Blood-Brain Barrier during Epileptogenesis and Epilepsy: A Cause, Consequence, or Both? Int J Mol Sci 2020; 21:E591. [PMID: 31963328 PMCID: PMC7014122 DOI: 10.3390/ijms21020591] [Citation(s) in RCA: 128] [Impact Index Per Article: 32.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2019] [Revised: 01/12/2020] [Accepted: 01/14/2020] [Indexed: 02/06/2023] Open
Abstract
The blood-brain barrier (BBB) is a dynamic, highly selective barrier primarily formed by endothelial cells connected by tight junctions that separate the circulating blood from the brain extracellular fluid. The endothelial cells lining the brain microvessels are under the inductive influence of neighboring cell types, including astrocytes and pericytes. In addition to the anatomical characteristics of the BBB, various specific transport systems, enzymes and receptors regulate molecular and cellular traffic across the BBB. While the intact BBB prevents many macromolecules and immune cells from entering the brain, following epileptogenic brain insults the BBB changes its properties. Among BBB alterations, albumin extravasation and diapedesis of leucocytes from blood into brain parenchyma occur, inducing or contributing to epileptogenesis. Furthermore, seizures themselves may modulate BBB functions, permitting albumin extravasation, leading to activation of astrocytes and the innate immune system, and eventually modifications of neuronal networks. BBB alterations following seizures are not necessarily associated with enhanced drug penetration into the brain. Increased expression of multidrug efflux transporters such as P-glycoprotein likely act as a 'second line defense' mechanism to protect the brain from toxins. A better understanding of the complex alterations in BBB structure and function following seizures and in epilepsy may lead to novel therapeutic interventions allowing the prevention and treatment of epilepsy as well as other detrimental neuro-psychiatric sequelae of brain injury.
Collapse
Affiliation(s)
- Wolfgang Löscher
- Department of Pharmacology, Toxicology and Pharmacy, University of Veterinary Medicine Hannover, 30559 Hannover, Germany
- Center of Systems Neuroscience, 30559 Hannover, Germany
| | - Alon Friedman
- Departments of Physiology and Cell Biology, Brain and Cognitive Sciences, Zlowotski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel;
- Department of Medical Neuroscience, Dalhousie University, Halifax, NS B3H 4R2, Canada
| |
Collapse
|
11
|
Shao Y, You D, Lou Y, Li J, Ying B, Cheng K, Weng W, Wang H, Yu M, Dong L. Controlled Release of Naringin in GelMA-Incorporated Rutile Nanorod Films to Regulate Osteogenic Differentiation of Mesenchymal Stem Cells. ACS OMEGA 2019; 4:19350-19357. [PMID: 31763559 PMCID: PMC6868884 DOI: 10.1021/acsomega.9b02751] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 08/26/2019] [Accepted: 10/30/2019] [Indexed: 06/10/2023]
Abstract
Naringin, a Chinese herbal medicine, has been demonstrated to concentration-dependently promote osteogenic differentiation of mesenchymal stem cells (MSCs). However, it remains a challenge to load naringin on coatings for osteogenesis and further control the release kinetics. Here, we demonstrated that the release behavior of naringin on rutile nanorod films could be controlled by either mixing naringin with gelatin methacryloyl (GelMA) before spinning onto the films or soaking the obtained GelMA-incorporated films with the naringin solution to achieve the distinct degradation-type release and diffusion-type release, respectively. We further revealed that the naringin-loaded coatings facilitated adhesion, proliferation and late differentiation, and mineralization of MSCs. Our findings provided a novel strategy to engineer the coatings with controlled release of naringin and emphasized the bioactivity of naringin for the osteogenic differentiation of MSCs.
Collapse
Affiliation(s)
- Yangjie Shao
- The
Affiliated Stomatologic Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang Province, China
| | - Dongqi You
- The
Affiliated Stomatologic Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang Province, China
| | - Yiting Lou
- The
Affiliated Stomatologic Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang Province, China
- Department
of Stomatology, The Affiliated Ningbo First Hospital, Zhejiang University, Ningbo 315010, Zhejiang Province, China
| | - Jianhua Li
- Hangzhou
Dental Hospital, Hangzhou 310006, Zhejiang Province, China
| | - Binbin Ying
- Department
of Stomatology, The Affiliated Ningbo First Hospital, Zhejiang University, Ningbo 315010, Zhejiang Province, China
| | - Kui Cheng
- School
of Materials Science and Engineering, State Key Laboratory of Silicon
Materials, Zhejiang University, Hangzhou 310027, Zhejiang Province, China
| | - Wenjian Weng
- School
of Materials Science and Engineering, State Key Laboratory of Silicon
Materials, Zhejiang University, Hangzhou 310027, Zhejiang Province, China
| | - Huiming Wang
- The
Affiliated Stomatologic Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang Province, China
| | - Mengfei Yu
- The
Affiliated Stomatologic Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang Province, China
- Department
of Stomatology, The Affiliated Ningbo First Hospital, Zhejiang University, Ningbo 315010, Zhejiang Province, China
- Hangzhou
Dental Hospital, Hangzhou 310006, Zhejiang Province, China
- School
of Materials Science and Engineering, State Key Laboratory of Silicon
Materials, Zhejiang University, Hangzhou 310027, Zhejiang Province, China
| | - Lingqing Dong
- The
Affiliated Stomatologic Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang Province, China
- School
of Materials Science and Engineering, State Key Laboratory of Silicon
Materials, Zhejiang University, Hangzhou 310027, Zhejiang Province, China
| |
Collapse
|